{"title":"Recognition of Suicide Risk.","authors":"John M Oldham","doi":"10.1097/PRA.0000000000000858","DOIUrl":"https://doi.org/10.1097/PRA.0000000000000858","url":null,"abstract":"","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 3","pages":"115"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marc J Weintraub, David J Miklowitz, Jessica K Jeffrey
{"title":"Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.","authors":"Marc J Weintraub, David J Miklowitz, Jessica K Jeffrey","doi":"10.1097/PRA.0000000000000853","DOIUrl":"https://doi.org/10.1097/PRA.0000000000000853","url":null,"abstract":"<p><p>We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major depressive disorder. Both patients participated in an open trial involving 2 drug administration sessions separated by one month (10 and 25 mg, respectively) along with 12 sessions of cognitive behavioral therapy. The first of the 2 patients had powerful and beneficial experiences on psilocybin that led to immediate and sustained antidepressant effects over the 7-month study. The second participant reported significant challenges with psilocybin and minimal to no antidepressant effects following the drug administration. We present the clinicians' experiences who treated both patients. Finally, we theorize and discuss areas of future research to elucidate how psilocybin can yield the greatest psychiatric benefit, the conditions within the patient that can lead to (or inhibit) psychiatric benefit, and the psychosocial environment that can best facilitate psilocybin therapy.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 3","pages":"169-172"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valerio Ricci, Alessandro Sarni, Domenico De Berardis, Thomas Fraccalini, Giovanni Martinotti, Giuseppe Maina
{"title":"Symptomatic Predictors of Suicidal Behavior in Early Psychosis: Systematic Review.","authors":"Valerio Ricci, Alessandro Sarni, Domenico De Berardis, Thomas Fraccalini, Giovanni Martinotti, Giuseppe Maina","doi":"10.1097/PRA.0000000000000860","DOIUrl":"https://doi.org/10.1097/PRA.0000000000000860","url":null,"abstract":"<p><p>Psychotic disorders, including schizophrenia, carry a substantial risk of suicide, particularly during the first-episode psychosis (FEP) phase. This narrative review aims to identify key symptomatic predictors of suicidal behavior in individuals experiencing FEP by thoroughly analyzing existing literature. Studies highlight that the highest suicide risk occurs around the initial presentation for psychiatric services. This critical period encompasses the month before and the 2 months after the first contact with mental health professionals. Severe depressive symptoms and a prolonged duration of untreated psychosis emerge as primary risk factors for suicidal behavior. Depression, when combined with cognitive impairments and a history of childhood trauma, significantly increases the risk of suicidality. These combined factors create a compounded effect, making it more difficult for individuals to cope and increasing their feelings of hopelessness and despair. In addition, poor premorbid functioning-referring to the level of psychological and social functioning before the onset of psychosis-and substance abuse, particularly the use of stimulants, further exacerbate the risk. Substance abuse can also intensify symptoms and impair judgment, leading to an increased likelihood of suicidal behavior. This review underscores the critical importance of timely, comprehensive, and tailored interventions. Early detection and intervention can significantly mitigate the risk of suicide in patients with FEP. Providing targeted treatments that address depressive symptoms, cognitive impairments, and substance abuse issues can improve overall outcomes and enhance the quality of life for these individuals. Comprehensive care approaches and strategies to improve functioning are also essential in reducing suicidality and promoting long-term recovery.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 3","pages":"125-138"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John C Markowitz, David Mintz, Michael E Thase, Samuel Dotson
{"title":"The 16-minute Hour: Combining Abbreviated Psychotherapy With Medication Visits. Part 2: Supportive Psychotherapy.","authors":"John C Markowitz, David Mintz, Michael E Thase, Samuel Dotson","doi":"10.1097/PRA.0000000000000851","DOIUrl":"https://doi.org/10.1097/PRA.0000000000000851","url":null,"abstract":"<p><p>Psychiatrists increasingly practice psychotherapy by integrating their therapeutic training into brief medication visits. Insurance companies reimburse this approach using the 90833 Current Procedural Terminology code, which corresponds to 16 to 37 minutes of add-on psychotherapy combined with pharmacotherapy. As scholarship focused on such short-form combined therapy is scarce, this 4-part series addresses the practice gap, providing guidance to practicing professionals. This installment addresses supportive psychotherapy, an elemental, affect-focused treatment with an evidence base for treating major depression.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 3","pages":"158-160"},"PeriodicalIF":1.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junting Liu, Brooke Ellen Delgoffe, Rachel Gabor, Shivy Sharma, Ajay K Parsaik
{"title":"Association of Thyroid Function With Depression: A Historical Cohort Study.","authors":"Junting Liu, Brooke Ellen Delgoffe, Rachel Gabor, Shivy Sharma, Ajay K Parsaik","doi":"10.1097/PRA.0000000000000840","DOIUrl":"10.1097/PRA.0000000000000840","url":null,"abstract":"<p><strong>Background: </strong>There is inconsistent evidence concerning the association between thyroid dysfunctions and depression. Therefore, we conducted this population-based study to investigate the relationship between thyroid-stimulating hormone (TSH) and depression using the Patient Health Questionnaire-9 (PHQ-9).</p><p><strong>Method: </strong>We included patients (≥18 y) who received care at the Marshfield Clinic Health System and completed a TSH level and a PHQ-9 within 2 weeks, between 2015 and 2020. We used a logistic regression model adjusted for covariates to estimate the effect of TSH level on clinically relevant depression (PHQ-9 score ≥10).</p><p><strong>Results: </strong>Our cohort included 31,099 patients, mean age 50.9±19.5 years, 73.5% females, and 96.3% White, 39.7% of whom had clinically relevant depression. The patients with clinically relevant depression had higher TSH levels compared with those without such depression (P=0.01). In this cohort, we found that low TSH levels (<0.5 mIU/L) and very elevated TSH levels (≥10 mIU/L) both had increased odds of being associated with clinically relevant depression: [1.30 (95% CI: 1.15-1.46) and OR 1.50 (95% CI: 1.25-1.81), respectively]. Subgroup analysis showed similar findings in patients with mood disorders, females, younger adults (<65 y), and those with untreated thyroid disorders. In males, only low TSH was associated with clinically relevant depression, whereas in patients with treated thyroid disorders, only very elevated TSH was associated with clinically relevant depression.</p><p><strong>Conclusions: </strong>In this large cross-sectional study, we found that low TSH and very elevated TSH levels were both associated with higher odds of depression. Similar trends were observed in patients with mood disorders, females, younger adults (<65 y), and those with untreated thyroid disorders. Large prospective population-based studies are needed to further investigate the relationship between TSH levels and clinical depression.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"74-81"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cannabis-induced Catatonia: A Case Study.","authors":"Darby Herkert, Matthew Majeske","doi":"10.1097/PRA.0000000000000849","DOIUrl":"10.1097/PRA.0000000000000849","url":null,"abstract":"<p><p>Catatonia is a diagnosis characterized by a combination of abnormal movements, behaviors, and withdrawal. It has been linked to mental health diagnoses such as schizophrenia and mood disorders. Catatonia is both traumatic for the patient and linked to multiple negative downstream medical diagnoses. Marijuana is a frequently utilized recreational drug that has been shown to have various neuropsychiatric effects in recent years. This report describes the case of a young adult male presenting with catatonia in the setting of cannabis use without other predisposing factors. It adds to the growing evidence of cannabis-associated catatonia, and it highlights the need for further research and increased counseling regarding the neuropsychiatric effects of marijuana.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"105-106"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From the Washington University (or Feighner) Psychiatric Diagnostic Criteria to DSM-III and Subsequent Versions: A Personal Perspective.","authors":"Sheldon H Preskorn","doi":"10.1097/PRA.0000000000000841","DOIUrl":"10.1097/PRA.0000000000000841","url":null,"abstract":"<p><p>The goal of this column is to give an autobiographical perspective on what I saw and learned as a trainee about the origins and the people behind the development of criteria-based psychiatric diagnosis. These individuals' own words are used to explain their rationale and goals. I further explain the transition from the Washington University (or Feighner) criteria to the Research Diagnostic Criteria to the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III). The column ends with an example of how research inclusion and exclusion criteria added to DSM-III diagnoses can result in positive results by making the populations being studied both more homogenous and discrete from one another.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"85-88"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ketamine: The Story of Modern Psychiatry's Most Fascinating Molecule.","authors":"Joseph McCullen Truett","doi":"10.1097/PRA.0000000000000839","DOIUrl":"https://doi.org/10.1097/PRA.0000000000000839","url":null,"abstract":"","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"113-114"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel Carmona-Farres, Ricardo Lopez-Escribano, Mercè Aubareda-Magriñà, Marta Serrallonga-Mercader, Iluminada Corripio Collado
{"title":"A Patient With Schizophrenia's Journey to an Autoimmune Encephalitis Diagnosis: Shedding Light on Common Clinical Biases.","authors":"Daniel Carmona-Farres, Ricardo Lopez-Escribano, Mercè Aubareda-Magriñà, Marta Serrallonga-Mercader, Iluminada Corripio Collado","doi":"10.1097/PRA.0000000000000848","DOIUrl":"10.1097/PRA.0000000000000848","url":null,"abstract":"<p><p>The interplay between psychiatric and neurological disorders often complicates diagnostic processes, leading to significant challenges in distinguishing between mental illnesses and neurological conditions. This complexity is further exacerbated by diagnostic overshadowing, a phenomenon where symptoms of one disorder may mask or alter the perception of the other. Through the lens of a nuanced case, we chronicle the journey of a 73-year-old male with longstanding schizophrenia whose later development of motor symptoms was initially attributed to side effects of his psychiatric medication. As his general condition tended to worsen over time, a more in-depth investigation revealed a more profound neurological underpinning, illustrating the perilous path of misdiagnosis that persisted for several months. We also interweave a brief review of analogous cases in the literature that underscore the impact of decision-making errors in medical practice, highlighting the necessity for critical thinking, continuous vigilance, and the implementation of strategies to mitigate diagnostic errors.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"100-104"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samuel Dotson, John C Markowitz, David Mintz, Michael E Thase
{"title":"The 16-minute Hour: Combining Abbreviated Psychotherapy With Medication Visits. Part 1: Introduction.","authors":"Samuel Dotson, John C Markowitz, David Mintz, Michael E Thase","doi":"10.1097/PRA.0000000000000838","DOIUrl":"10.1097/PRA.0000000000000838","url":null,"abstract":"<p><p>Psychiatrists increasingly practice psychotherapy by integrating their therapeutic training into brief medication visits. Insurance companies reimburse this approach using the 90833 Current Procedural Terminology code, which corresponds to 16-37 minutes of add-on psychotherapy combined with pharmacotherapy. As scholarship focused on such short-form combined therapy is scarce, this 4-part series addresses this practice gap, providing guidance to practicing professionals. This introductory installment reviews recent evolutions in psychotherapy training, the existing literature on abbreviating psychotherapy techniques, and some general guidelines and principles for adapting psychotherapy to shortened visits and selecting a specific therapeutic modality.</p>","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 2","pages":"89-94"},"PeriodicalIF":1.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}